News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
730,517 Results
Type
Article (43554)
Company Profile (282)
Press Release (686681)
Multimedia
Podcasts (68)
Webinars (13)
Section
Business (212703)
Career Advice (2180)
Deals (36804)
Drug Delivery (108)
Drug Development (83265)
Employer Resources (176)
FDA (17016)
Job Trends (15521)
News (359486)
Policy (34465)
Tag
Academia (2655)
Accelerated approval (6)
Adcomms (22)
Allergies (93)
Alliances (52191)
ALS (99)
Alzheimer's disease (1409)
Antibody-drug conjugate (ADC) (140)
Approvals (17012)
Artificial intelligence (283)
Autoimmune disease (23)
Automation (17)
Bankruptcy (371)
Best Places to Work (11988)
BIOSECURE Act (19)
Biosimilars (113)
Biotechnology (188)
Bladder cancer (81)
Brain cancer (27)
Breast cancer (294)
Cancer (2367)
Cardiovascular disease (185)
Career advice (1825)
Career pathing (30)
CAR-T (170)
Cell therapy (464)
Cervical cancer (20)
Clinical research (67767)
Collaboration (891)
Company closure (2)
Compensation (568)
Complete response letters (21)
COVID-19 (2702)
CRISPR (47)
C-suite (259)
Cystic fibrosis (105)
Data (2349)
Decentralized trials (2)
Denatured (29)
Depression (47)
Diabetes (292)
Diagnostics (6606)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (122)
Drug pricing (112)
Drug shortages (29)
Duchenne muscular dystrophy (99)
Earnings (89799)
Editorial (41)
Employer branding (21)
Employer resources (150)
Events (117374)
Executive appointments (764)
FDA (18434)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (789)
Gene editing (116)
Generative AI (21)
Gene therapy (337)
GLP-1 (780)
Government (4649)
Grass and pollen (6)
Guidances (158)
Healthcare (19409)
Huntington's disease (25)
IgA nephropathy (27)
Immunology and inflammation (130)
Indications (30)
Infectious disease (2853)
Inflammatory bowel disease (146)
Inflation Reduction Act (8)
Influenza (56)
Intellectual property (100)
Interviews (338)
IPO (16990)
IRA (43)
Job creations (3962)
Job search strategy (1553)
Kidney cancer (10)
Labor market (43)
Layoffs (504)
Leadership (17)
Legal (8381)
Liver cancer (78)
Lung cancer (330)
Lymphoma (159)
Machine learning (9)
Management (61)
Manufacturing (352)
MASH (78)
Medical device (14141)
Medtech (14146)
Mergers & acquisitions (20393)
Metabolic disorders (749)
Multiple sclerosis (84)
NASH (16)
Neurodegenerative disease (102)
Neuropsychiatric disorders (27)
Neuroscience (1983)
NextGen: Class of 2025 (6783)
Non-profit (4558)
Now hiring (40)
Obesity (395)
Opinion (234)
Ovarian cancer (81)
Pain (95)
Pancreatic cancer (88)
Parkinson's disease (155)
Partnered (22)
Patents (249)
Patient recruitment (117)
Peanut (49)
People (59495)
Pharmaceutical (77)
Pharmacy benefit managers (19)
Phase I (21158)
Phase II (29799)
Phase III (22238)
Pipeline (1382)
Policy (154)
Postmarket research (2633)
Preclinical (8988)
Press Release (71)
Prostate cancer (112)
Psychedelics (31)
Radiopharmaceuticals (258)
Rare diseases (398)
Real estate (6317)
Recruiting (66)
Regulatory (23668)
Reports (47)
Research institute (2400)
Resumes & cover letters (367)
Rett syndrome (6)
RNA editing (5)
RSV (45)
Schizophrenia (75)
Series A (135)
Series B (92)
Service/supplier (15)
Sickle cell disease (55)
Special edition (17)
Spinal muscular atrophy (153)
Sponsored (33)
Startups (3801)
State (2)
Stomach cancer (13)
Supply chain (72)
Tariffs (51)
The Weekly (37)
Vaccines (748)
Venture capitalists (43)
Weight loss (262)
Women's health (38)
Worklife (17)
Date
Today (150)
Last 7 days (984)
Last 30 days (3153)
Last 365 days (33322)
2025 (12132)
2024 (36180)
2023 (41143)
2022 (52394)
2021 (57129)
2020 (55685)
2019 (48421)
2018 (36500)
2017 (33733)
2016 (33293)
2015 (39382)
2014 (32964)
2013 (28116)
2012 (30365)
2011 (30952)
2010 (28779)
Location
Africa (778)
Alabama (54)
Alaska (7)
Arizona (248)
Arkansas (14)
Asia (41047)
Australia (6761)
California (6498)
Canada (2086)
China (557)
Colorado (278)
Connecticut (290)
Delaware (164)
Europe (89758)
Florida (959)
Georgia (216)
Hawaii (1)
Idaho (60)
Illinois (577)
India (26)
Indiana (333)
Iowa (11)
Japan (174)
Kansas (110)
Kentucky (26)
Louisiana (12)
Maine (71)
Maryland (947)
Massachusetts (4849)
Michigan (246)
Minnesota (417)
Mississippi (2)
Missouri (89)
Montana (29)
Nebraska (25)
Nevada (68)
New Hampshire (66)
New Jersey (1831)
New Mexico (29)
New York (1820)
North Carolina (1042)
North Dakota (9)
Northern California (2864)
Ohio (214)
Oklahoma (14)
Oregon (38)
Pennsylvania (1443)
Puerto Rico (13)
Rhode Island (33)
South America (1199)
South Carolina (25)
South Dakota (1)
Southern California (2434)
Tennessee (105)
Texas (970)
United States (24518)
Utah (194)
Virginia (163)
Washington D.C. (66)
Washington State (578)
West Virginia (3)
Wisconsin (59)
730,517 Results for "micron products inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Micron Solutions, Inc. Board Announces Proposal for Stock Splits
Micron Solutions, Inc., through its wholly-owned subsidiary, Micron Products, Inc. announced the Board’s approval of a proposal to effect a 1-for-1,000 reverse stock split of the Company’s Common Stock, followed immediately by a 1,000 to 1 forward stock split for the Company’s Common Stock, which Stock Splits will be enacted through the filing of amendments to the Company’s Certificate of Incorporation with the Secretary of State of the State of Delaware.
October 2, 2023
·
8 min read
Press Releases
Micron Biomedical Extends Series A Financing to 33+ Million to Accelerate Commercialization of Needle-Free Therapeutics and Vaccines
January 16, 2025
·
4 min read
Press Releases
Exyte Receives Micron’s Outstanding Supplier Performance Award in Supplier Diversity
November 26, 2024
·
2 min read
Drug Development
Micron Biomedical Announces The Lancet Publication of Positive Phase 1/2 Data From First Clinical Trial of Needle-Free Vaccines in Children
Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the transport, storage, and administration of drugs and vaccines, today announced the publication of its positive Measles and Rubella (MR) Phase 1/2 trial data in The Lancet Medical Journal.
May 1, 2024
·
5 min read
Press Releases
Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without Needles
January 14, 2025
·
4 min read
Press Releases
UPDATE - Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without Needles
January 14, 2025
·
4 min read
Press Releases
CEPI and Micron Biomedical Accelerate Needle-Free Vaccines against Disease X with $3.7 Million Grant to Advance Learnings from COVID-19
January 9, 2025
·
6 min read
Business
Micron Biomedical Appoints Global Health Pioneer and Champion of Vaccine Access, Dr. Seth Berkley, as Scientific Advisor to the CEO
Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the transport, storage, and administration of drugs and vaccines, announced the appointment of global public health pioneer, Dr. Seth Berkley, as scientific advisor to the CEO.
February 27, 2024
·
3 min read
Press Releases
Micron Biomedical Secures $43 Million in Total Grant Support to Improve Coverage of Measles and Rubella Vaccine and Accelerate World’s First Phase 2 Trial of Needle-Free Drug and Vaccine Technology in Infants
January 8, 2025
·
4 min read
BioMidwest
Micron Biomedical Receives $23.6 Million to Accelerate Commercial Manufacturing of Needle-Free Vaccines and to Help Eradicate Measles
Micron Biomedical announced a $23.6 million grant from the Bill & Melinda Gates Foundation that will fund mass production of needle-free vaccines.
November 16, 2023
·
4 min read
1 of 73,052
Next
